In summary, modulation of human nSMase2 activity could be a therapeutic approach worth pursuing for the treatment of a number of neurodegenerative diseases and cambinol could be used as an alternative prototype inhibitor with similar inhibitory potency but improved solubility over currently available compounds. The gene discussed is SMPD3; the disease is neurodegenerative disease.